| Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) (NCT07770815) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-09-30 |
| A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body (NCT07649265) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-09-15 |
| A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation (NCT07759154) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-08-20 |
| A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder (NCT07767903) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-08-07 |
| A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder (NCT07759128) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-07-28 |
| A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney Function (NCT07713758) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-07-17 |
| A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body (NCT07525960) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-07-07 |
| A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together (NCT07446400) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-03-31 |
| A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults (NCT07455084) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-03-20 |
| A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (NCT07314333) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-02-05 |
| A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults (NCT07329621) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-01-15 |
| A Study of JNT-517 in Participants With Phenylketonuria (PKU) (NCT06971731) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-10-20 |
| A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis (NCT07209761) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-10-16 |
| A Long-Term Study of JNT-517 in Participants With Phenylketonuria (NCT06628128) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-08-11 |
| A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria (NCT06637514) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-07-16 |
| A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure (NCT06795399) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-04-30 |
| A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's (NCT06928142) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-04-23 |
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety (NCT06973577) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-03-26 |
| A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s) (NCT06799520) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-03-17 |
| A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954 (NCT06937593) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-03-13 |
| A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women (NCT07305779) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-03-07 |
| A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia (NCT06894212) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-02-28 |
| Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue (NCT06740526) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2024-11-19 |
| A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode (NCT07549581) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2024-11-07 |
| A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels (NCT07253441) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2024-08-29 |
| How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants (NCT07573449) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2024-01-22 |
| A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy Men (NCT07314320) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2023-11-20 |
| A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis. (NCT06143371) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2023-08-21 |
| A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion (NCT06372210) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2023-06-26 |
| A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia (NCT05848700) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2023-06-21 |
| A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder (NCT05729373) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2023-03-08 |
| Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects (NCT07486895) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2023-03-08 |
| A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) (NCT04782258) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2023-01-23 |
| A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication (NCT05628103) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-12-19 |
| A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder (NCT05593029) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-11-09 |
| First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria (NCT05781399) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-10-31 |
| A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine (NCT07465731) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-10-27 |
| A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women (NCT07542847) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-09-19 |
| Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder (NCT05536414) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-09-12 |
| A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline (NCT05189977) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-09-07 |
| A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia (NCT05463770) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-08-30 |
| Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety (NCT05504486) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-08-29 |
| A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD) (NCT05428033) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-07-11 |
| A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) (NCT04786574) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-07-01 |
| A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard (NCT05402111) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-06-13 |
| A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease) (NCT05418101) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-04-28 |
| Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB (NCT05221502) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-04-12 |
| Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) (NCT05248659) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-04-05 |
| Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) (NCT05248646) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-03-15 |
| A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder (NCT05257265) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-02-02 |
| A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder (NCT05113953) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2021-12-22 |
| Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment (NCT05066724) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2021-09-15 |
| A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia. (NCT04865835) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2021-05-12 |
| Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder (NCT04830215) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2021-04-01 |
| A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder (NCT04786730) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2021-03-09 |
| Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder (NCT04770285) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2021-02-25 |
| Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (NCT04464564) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2020-09-11 |
| Safety and Efficacy Study of VIS649 for IgA Nephropathy (NCT04287985) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2020-07-20 |
| Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (NCT04408755) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2020-07-13 |
| A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder (NCT04398225) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2020-06-11 |
| Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation (NCT03850509) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2020-02-25 |
| A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870 (NCT04241965) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2020-02-18 |
| Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148 (NCT04258839) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2020-01-23 |
| Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD) (NCT04186403) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2020-01-13 |
| A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. (NCT04115319) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-11-21 |
| A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia (NCT04109950) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-11-20 |
| Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder (NCT04174170) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-10-30 |
| Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (NCT04174365) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-10-30 |
| Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD (NCT04124614) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-10-17 |
| A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder (NCT04100096) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-10-17 |
| A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia (NCT04092686) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-10-14 |
| Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD) (NCT04081363) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-10-07 |
| A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia (NCT04072354) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-09-17 |
| A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging (NCT04038957) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-08-07 |
| A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder (NCT04030143) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-08-01 |
| A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® (NCT03892889) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-04-29 |
| Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder (NCT03872596) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-03-27 |
| Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia (NCT03896945) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-02-15 |
| A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder (NCT03605849) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-02-14 |
| A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder (NCT03854409) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-01-31 |
| A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder (NCT03605836) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2019-01-16 |
| A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis (NCT03678688) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2018-10-18 |
| Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder (NCT03661983) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2018-10-13 |
| A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type (NCT03594123) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2018-10-11 |
| First in Human Study to Assess Safety of VIS649 in Healthy Subjects (NCT03719443) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2018-10-09 |
| A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder (NCT03538691) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2018-07-13 |
| A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder (NCT03643159) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2018-06-28 |
| A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic (NCT03568500) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2018-05-21 |
| A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type (NCT03548584) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2018-05-16 |
| Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder (NCT03420222) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2018-01-18 |
| The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder (NCT03324581) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2017-11-09 |
| A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. (NCT03287869) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2017-10-24 |
| Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (NCT03393520) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2017-10-13 |
| Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders (NCT03292848) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2017-10-10 |
| A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder (NCT03257865) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2017-09-19 |
| A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder (NCT03259555) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2017-09-14 |